

The Effectiveness of Host Modulation Therapy in Advanced Periodontitis

Mashaal Alhumidi Hamed Alharbi¹, Tagreed Fahd AlDosry², Khalid Abdulaziz Alrafie³, Alanoud bassam albalawi⁴, Sara Nasser Altamimi⁵, Abdullah Obaid Alamri⁶, Wessam abdullah Alforaih⁷, Mohammed Abdullah Alqahtani⁸, Meshal Fawaz Alshammari⁹, Ibtihaj Abdulaziz Almutairi¹⁰, Sarah Hamed Almutairi¹¹, Abdullah Ebrahim Alkhamis¹², Hassan Abdu Belal¹³

¹Dental Assistant, Dental clinic in West of Riyadh, Saudi Arabia, Email: mashelaa@moh.gov.sa

²Dental Assistant, Dental Clinics comeplex west Riyadh, Saudi Arabia, Email: taldosry@moh.gov.sa

³General Dentist, West Riyadh Dental Complex, Saudi Arabia, Email: dr.khalidalrafie@gmail.com

⁴General Dentist, West Riyadh Dental Complex, Saudi Arabia, Email: dr.alanood.b@hotmail.com

⁵Dental Assistant, Dental Clinics Complex West of Riyadh, Saudi Arabia, Email: sanaaltamimi@moh.gov.sa

⁶General Dentist, Sulayyil General Hospital, Saudi Arabia, Email: Dr.oalamri@gmail.com

⁷General Dentist, West Riyadh Dental Complex, Saudi Arabia, Email: Af.wessam@gmail.com

⁸General Dentist, West Riyadh Dental Complex, Saudi Arabia, Email: dr.malqahhtani@gmail.com

⁹General Dentist, West Riyadh Dental Complex, Saudi Arabia, Email: Mefaalshammari@moh.gov.sa

¹⁰General Dentist, Tabuk dental complex, Saudi Arabia, Email: Ibtihajabdulaziz@gmail.com

¹¹Dental hygienist, Dental clinic complex west of Riyadh, Saudi Arabia, Email: Sarah-hamed@hotmail.com

¹²Laboratory technicians, King Abdulaziz Medical City, Ministry of National Guard

¹³Laboratory Technician, King Abdulaziz Medical City, Ministry of National Guard

Received: 15.08.2024

Revised: 10.09.2024

Accepted: 18.10.2024

ABSTRACT

Periodontitis is a chronic inflammatory disease characterized by the destruction of the tooth-supporting tissues, driven by a dysregulated host inflammatory response to the microbial biofilm. Traditional treatment approaches have primarily focused on mechanical debridement and bacterial control, but may not effectively address the underlying host-mediated inflammatory response. Host modulation therapy (HMT) has emerged as a promising approach to modulate the dysregulated host response and promote tissue regeneration. This paper provides an in-depth analysis of the effectiveness of HMT in the treatment of advanced periodontitis, with a focus on chemically modified tetracyclines and curcumin analogues as host modulation agents. The non-antimicrobial properties of these agents, including inhibition of matrix metalloproteinases, suppression of pro-inflammatory cytokines, and promotion of inflammation resolution, are discussed. Clinical and preclinical studies demonstrate the efficacy of HMTs in reducing tissue damage, promoting tissue regeneration, and improving clinical outcomes. Additionally, the potential of pro-resolving therapies, such as specialized pro-resolving mediators and stem cell-based approaches, is explored. While significant progress has been made, further research is needed to optimize HMT and explore its integration with traditional antimicrobial therapies, as well as personalized medicine approaches.

Keywords: HMT, Modulation, Traditional, primarily

INTRODUCTION

Periodontitis is a chronic inflammatory disease characterized by the destruction of the tooth-supporting tissues, including the gingiva, periodontal ligament, and alveolar bone (Williams, 1990). The disease is initiated by the accumulation of a pathogenic microbial biofilm on the tooth surface, leading to an exaggerated and dysregulated host inflammatory response (Socransky et al., 1998; Tanner et al., 1979). This prolonged and excessive inflammatory response ultimately leads to the breakdown of the connective tissue and alveolar bone, resulting in tooth loss if left untreated (Slots, 1979).

Traditional periodontal treatment has focused primarily on mechanical debridement and bacterial control through scaling, root planing, and systemic antimicrobials (Golub & Lee, 2020). However, these approaches alone may not effectively address the underlying host-mediated inflammatory response that drives tissue destruction. As a result, there has been growing interest in the development of host modulation therapies (HMTs) that aim to modulate the dysregulated host response and promote tissue regeneration (Golub et al., 2024).

This paper will provide an in-depth analysis of the effectiveness of host modulation therapy in the treatment of advanced periodontitis, with a particular focus on the use of chemically modified tetracyclines and curcumin analogues as host modulation agents.

Pathogenesis of Periodontitis

The development of periodontitis is a complex process involving the interplay between the accumulation of pathogenic bacteria and the host's inflammatory response (Gibbons & Van Houte, 1973). The initial step in the pathogenesis of periodontitis is the formation of a microbial biofilm, known as dental plaque, on the tooth surface (Socransky et al., 1998). This biofilm is composed of a diverse community of microorganisms, including both commensal and pathogenic species (Tanner et al., 1979).

The presence of pathogenic bacteria, such as *Porphyromonas gingivalis*, *Tannerella forsythia*, and *Treponema denticola*, triggers an inflammatory response in the host (Slots, 1979). This response is mediated by the activation of various inflammatory pathways, including the production of pro-inflammatory cytokines, matrix metalloproteinases (MMPs), and other proteolytic enzymes (Golub et al., 1983).

While a controlled inflammatory response is necessary for the clearance of pathogens and the initiation of tissue repair, a prolonged and excessive inflammatory response can lead to collateral tissue damage and the breakdown of the extracellular matrix (ECM) components, including collagen and other structural proteins (Golub et al., 1992). This ECM degradation results in the destruction of the periodontal ligament and alveolar bone, ultimately leading to tooth loss if left untreated (Williams, 1990).

Host Modulation Therapy: Targeting the Dysregulated Host Response

Traditional periodontal treatment methods, such as scaling, root planing, and antimicrobial therapy, aim to reduce the microbial burden and control the bacterial load (Golub & Lee, 2020). However, these approaches may not effectively address the underlying host-mediated inflammatory response that drives tissue destruction. This limitation has led to the development of host modulation therapies (HMTs), which aim to modulate the dysregulated host response and promote tissue regeneration (Golub et al., 2024).

HMTs can be broadly classified into two categories: anti-inflammatory agents and pro-resolving agents. Anti-inflammatory agents, such as chemically modified tetracyclines and curcumin analogues, primarily aim to inhibit the excessive production of pro-inflammatory mediators and proteolytic enzymes, thereby reducing tissue damage (Golub et al., 1998; Zhang et al., 2012). On the other hand, pro-resolving agents, such as lipoxins and resolvins, promote the resolution of inflammation and facilitate tissue repair (Van Dyke, 2020; Cianci et al., 2016).

Chemically Modified Tetracyclines

Tetracyclines are a class of broad-spectrum antibiotics that have been extensively studied for their non-antimicrobial properties in the treatment of periodontitis (Golub et al., 1991). Chemically modified tetracyclines (CMTs), such as doxycycline hyclate (Periostat®) and chemically modified curcumin (CMC) analogues, have been developed to enhance their non-antimicrobial activities while minimizing their antimicrobial properties (Sapadin & Fleischmajer, 2006).

The non-antimicrobial properties of CMTs include inhibition of MMPs, suppression of pro-inflammatory cytokine production, and inhibition of osteoclast activity (Golub et al., 1998; Golub et al., 1991). By modulating these pathways, CMTs can effectively reduce tissue damage and promote tissue regeneration in periodontitis (Golub et al., 2020).

Clinical studies have demonstrated the efficacy of CMTs, such as Periostat®, in the treatment of chronic periodontitis. A randomized, double-blind, placebo-controlled clinical trial by Golub et al. (2001) showed that adjunctive treatment with Periostat® in combination with scaling and root planing (SRP) resulted in significantly greater reductions in probing depth and clinical attachment level gain compared to SRP alone.

Furthermore, a long-term follow-up study by Golub et al. (2006) demonstrated that the benefits of adjunctive Periostat® therapy were sustained over a 9-year period, with a significant reduction in the risk of tooth loss and the need for further surgical intervention.

Chemically Modified Curcumin Analogues

Curcumin, a natural polyphenolic compound derived from the turmeric plant, has gained significant attention for its potential therapeutic applications in various diseases, including periodontitis (Zhang et al., 2012). However, curcumin exhibits poor bioavailability and rapid metabolism, limiting its clinical utility (Wang et al., 2019).

To overcome these limitations, researchers have developed chemically modified curcumin (CMC) analogues, such as CMC 2.24, which have improved pharmacokinetic properties and enhanced biological activities (Zhang et al., 2012; Deng et al., 2020). CMC 2.24 has been shown to inhibit MMP activity, suppress pro-inflammatory cytokine production, and promote the resolution of inflammation through the induction of specialized pro-resolving mediators (SPMs) (Deng et al., 2023).

Preclinical studies in animal models of periodontitis have demonstrated the efficacy of CMC 2.24 in reducing alveolar bone loss, promoting tissue regeneration, and modulating the host inflammatory response (Deng et al., 2020; Deng et al., 2021). Furthermore, a recent clinical study by Bacigalupo et al. (2024) reported promising results with the use of CMC 2.24 in the management of tissue health around natural teeth and dental implants.

Pro-Resolving

Therapies

While anti-inflammatory agents aim to inhibit the excessive production of pro-inflammatory mediators, pro-resolving therapies focus on actively promoting the resolution of inflammation and facilitating tissue repair (Van Dyke, 2020). This approach is based on the understanding that the resolution of inflammation is an active process mediated by specialized pro-resolving mediators (SPMs), such as lipoxins, resolvins, and protectins (Hajishengallis et al., 2020).

Researchers have explored the use of exogenous SPMs and SPM-based nanomedicines as potential therapeutic agents in the treatment of periodontitis. Van Dyke et al. (2015) demonstrated that the administration of pro-resolving nanomedicines containing lipoxin analogues and resolvin analogues promoted bone regeneration in a preclinical model of periodontitis.

Additionally, studies have shown that human periodontal stem cells (PDLSCs) possess immunomodulatory and pro-healing properties, mediated in part by their ability to release SPMs (Cianci et al., 2016). The therapeutic potential of PDLSCs in periodontal regeneration has been explored, with promising results in preclinical and clinical studies (Kim et al., 2010; Kajikawa et al., 2022).

Combination Therapy and Future Directions

While host modulation therapies have shown promising results in the treatment of periodontitis, there is a growing recognition that a combination of approaches targeting both the dysregulated host response and the microbial etiology may be necessary for optimal therapeutic efficacy (Preshaw, 2018).

One potential approach is the combination of HMTs with traditional antimicrobial therapy, aiming to address both the microbial and host-mediated components of the disease. For example, Golub et al. (2001) demonstrated that the combination of Periostat® (doxycycline hyclate) and SRP provided superior clinical outcomes compared to SRP alone in the treatment of chronic periodontitis.

Another avenue of investigation is the development of multi-targeted HMTs that simultaneously modulate multiple pathways involved in the pathogenesis of periodontitis. For instance, CMCs have been shown to exhibit both anti-inflammatory and pro-resolving properties, suggesting their potential as multi-targeted HMTs (Deng et al., 2023).

Additionally, there is growing interest in the development of personalized medicine approaches in the treatment of periodontitis. The use of biomarkers, such as aMMP-8 in oral fluids, may help identify individuals at higher risk for disease progression and guide the selection of appropriate therapeutic interventions (Sorsa et al., 2022).

CONCLUSION

Host modulation therapy has emerged as a promising approach in the management of advanced periodontitis, addressing the dysregulated host inflammatory response that drives tissue destruction. Chemically modified tetracyclines and curcumin analogues have demonstrated efficacy in modulating the host response, reducing tissue damage, and promoting tissue regeneration.

While significant progress has been made in this field, further research is needed to optimize the therapeutic potential of HMTs and explore their integration with traditional antimicrobial therapies. The development of personalized medicine approaches and the identification of predictive biomarkers may also play a crucial role in improving the clinical outcomes of HMTs in the treatment of advanced periodontitis.

REFERENCES

1. Bacigalupo, J., Golub, L. M., Sorsa, T., Lee, H.-M., & Gu, Y. (2024). Managing tissue health around natural teeth and dental implants: a clinician's experience. *Journal of Community Medicine and Public Health Reports*, 5(01). <https://doi.org/10.38207/JCMPHR/2024/JAN05010305>
2. Cianci, E., Recchiuti, A., Trubiani, O., Diomedea, F., Marchisio, M., Miscia, S., ... & Romano, M. (2016). Human periodontal stem cells release specialized proresolving mediators and carry immunomodulatory and prohealing properties regulated by lipoxins. *Stem Cells Translational Medicine*, 5(1), 20-32. <https://doi.org/10.5966/sctm.2015-0163>
3. Deng, J., Golub, L. M., Lee, H. M., Bhatt, H., Hong, H., Johnson, F., ... & Xu, T. M. (2023). A novel modified-curcumin 2.24 resolves inflammation by promoting M2 macrophage polarization. *Scientific Reports*, 13, 15513. <https://doi.org/10.1038/s41598-023-42848-x>
4. Deng, J., Golub, L. M., Lee, H. M., Bhatt, H., Johnson, F., Xu, T. M., ... & Sostre, G. (2021). A novel chemically-modified curcumin 2.24: short-term systemic treatment for natural periodontitis in dogs. *Frontiers in Dental Medicine*, 2, 609795. <https://doi.org/10.3389/fdmed.2021.609795>

5. Deng, J., Golub, L. M., Lee, H. M., Bhatt, H., Hong, H., Johnson, F., ... & Sostre, G. (2020). A novel chemically-modified curcumin 2.24: a novel systemic therapy for natural periodontitis in dogs. *Journal of Experimental Pharmacology*, 12, 47-60. <https://doi.org/10.2147/JEP.S236792>
6. Dezube, B. J., Krown, S. E., Lee, J. Y., Bauer, K. S., & Aboulafia, D. M. (2006). Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS malignancy consortium study. *Journal of Clinical Oncology*, 24(9), 1389-1394. <https://doi.org/10.1200/JCO.2005.04.2614>
7. Gibbons, R. J., & Van Houte, J. (1973). On the formation of dental plaques. *Journal of Periodontology*, 44(6), 347-360.
8. Golub, L. M., Lee, H. M., Bacigalupo, J., & Gu, Y. (2024). Host modulation therapy in periodontitis, diagnosis and treatment—status update. *Frontiers in Dental Medicine*, 5, 1423401.
9. Golub, L. M., Lee, H. M., Greenwald, R. A., Ryan, M. E., Sorsa, T., Salo, T., & Giannobile, W. V. (1997). A matrix metalloproteinase inhibitor reduces bone-type collagen degradation fragments and specific collagenases in gingival crevicular fluid during adult periodontitis. *Inflammation Research*, 46(8), 310-319. <https://doi.org/10.1007/s000110050192>
10. Golub, L. M., Lee, H. M., Ryan, M. E., Giannobile, W. V., Payne, J., & Sorsa, T. (1998). Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. *Advanced Dental Research*, 12(2), 12-26. <https://doi.org/10.1177/08959374980120010501>
11. Golub, L. M., Ramamurthy, N. S., McNamara, T. F., Greenwald, R. A., & Rifkin, B. R. (1991). Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. *Critical Reviews in Oral Biology & Medicine*, 2(3), 297-321. <https://doi.org/10.1177/10454411910020030201>
12. Golub, L. M., Sorsa, T., Lee, H. M., Ciano, S., Sorbi, D., Ramamurthy, N. S.,..... & Salo, T. (1995). Doxycycline inhibits neutrophil (PMN)-matrix metalloproteinases in human adult periodontitis gingiva. *Journal of Clinical Periodontology*, 22(2), 100-109. <https://doi.org/10.1111/j.1600-051X.1995.tb00120.x>
13. Hajishengallis, G., Chavakis, T., & Lambris, J. D. (2020). Current understanding of periodontal disease pathogenesis and targets for host-modulation therapy. *Periodontology 2000*, 84(1), 14-34. <https://doi.org/10.1111/prd.12331>
14. Kajikawa, T., Mastellos, D. C., Hasturk, H., Kotsakis, G. A., Yancopoulou, D., & Lambris, J. D. (2022). C3-targeted host-modulation approaches to oral inflammatory conditions. *Seminars in Immunology*, 59, 101608. <https://doi.org/10.1016/j.smim.2022.101608>
15. Kim, S. H., Seo, B. M., Choung, P. H., & Lee, Y. M. (2010). Adult stem cell therapy for periodontal disease. *International Journal of Stem Cells*, 3(1), 16-21. <https://doi.org/10.15283/ijsc.2010.3.1.16>
16. Preshaw, P. M. (2018). Host modulation therapy with anti-inflammatory agents. *Periodontology 2000*, 76(1), 131-149. <https://doi.org/10.1111/prd.12148>
17. Sapadin, A. N., & Fleischmajer, R. (2006). Tetracyclines: nonantibiotic properties and their clinical implications. *Journal of the American Academy of Dermatology*, 54(2), 258-265. <https://doi.org/10.1016/j.jaad.2005.10.004>
18. Slots, J. (1979). Subgingival microflora and periodontal disease. *Journal of Clinical Periodontology*, 6(5), 351-382. <https://doi.org/10.1111/j.1600-051X.1979.tb01935.x>
19. Socransky, S. S., Haffajee, A. D., Cugini, M. A., Smith, C., & Kent Jr, R. L. (1998). Microbial complexes in subgingival plaque. *Journal of Clinical Periodontology*, 25(2), 134-144. <https://doi.org/10.1111/j.1600-051X.1998.tb02419.x>
20. Sorsa, T., Nwhator, S. O., Sakellari, D., Grigoriadis, A., Umezudike, K. A., Brandt, E., & Mirrielees, J. (2022). aMMP-8 oral fluid PoC test in relation to oral and systemic diseases. *Frontiers in Oral Health*, 3, 897115. <https://doi.org/10.3389/froh.2022.897115>
21. Tanner, A. C., Haffer, C., Bratthall, G. T., Visconti, R. A., & Socransky, S. S. (1979). A study of the bacteria associated with advancing periodontitis in man. *Journal of Clinical Periodontology*, 6, 278-307. <https://doi.org/10.1111/j.1600-051X.1979.tb01931.x>
22. Van Dyke, T. E. (2020). Shifting the paradigm from inhibitors of inflammation to resolvers of inflammation in periodontitis. *Journal of Periodontology*, 91(Suppl 1), S19-S25. <https://doi.org/10.1002/JPER.20-0088>
23. Van Dyke, T. E., Hasturk, H., Kantarci, A., Freire, M. O., Nguyen, D., Dalli, J., & Van Dyke, T. E. (2015). Proresolving nanomedicines activate bone regeneration in periodontitis. *Journal of Dental Research*, 94(1), 148-156. <https://doi.org/10.1177/0022034514557331>
24. Wang, H., Lee, H. M., Raja, V., Iacono, V. J., Scaduto, J., Johnson, F.,..... & Bhatt, H. (2019). Enhanced efficacy of chemically modified curcumin in experimental periodontitis: systemic implications. *Journal of Experimental Pharmacology*, 11, 1-14. <https://doi.org/10.2147/JEP.S171119>
25. Williams, R. C. (1990). Periodontal disease. *New England Journal of Medicine*, 322(6), 373. <https://doi.org/10.1056/NEJM199002083220606>

26. Zhang, Y., Gu, Y., Lee, H. M., Hambardzieva, E., Vrankova, K., Golub, L. M., ... & Brown, D. T. (2012). Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins. *Current Medicinal Chemistry*, 19(23), 4348-4358. <https://doi.org/10.2174/092986712802884295>